ConductScience.org, home

Paper36737488

Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.

Zeng H and 6 others. Clin Exp Med, 2023. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis. Papers, record 36737488. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36737488

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
PubMed
Journal
Clin Exp Med
PubMed
Year
2023
PubMed
Publication types
Systematic Review, Journal Article, Network Meta-Analysis
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.47
iCite
Revised in PubMed
2025-06-23
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
Sorafenib
Bayes Theorem

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126910784A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.Liver Int2016https://conductscience.org/library/papers/26910784PubMed
229498924SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.J Clin Oncol2018https://conductscience.org/library/papers/29498924PubMed
334245592Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?Hepatology2021https://conductscience.org/library/papers/34245592PubMed
426455499Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.Eur J Nucl Med Mol Imaging2016https://conductscience.org/library/papers/26455499PubMed
530791765Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.Expert Rev Gastroenterol Hepatol2019https://conductscience.org/library/papers/30791765PubMed
628648803Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol2017https://conductscience.org/library/papers/28648803PubMed
79862851Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.Hepatology1999https://conductscience.org/library/papers/9862851PubMed
828781171
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Lancet Oncol2017https://conductscience.org/library/papers/28781171PubMed
932272656Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis.Cancers (Basel)2020https://conductscience.org/library/papers/32272656PubMed
1031421157Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019https://conductscience.org/library/papers/31421157PubMed
1118650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1232782275Targeted therapy for hepatocellular carcinoma.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32782275PubMed
1324750853Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.Liver Int2015https://conductscience.org/library/papers/24750853PubMed
1417519900Mechanisms of adverse effects of anti-VEGF therapy for cancer.Br J Cancer2007https://conductscience.org/library/papers/17519900PubMed
1519095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed
1634771591Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy.Cancers (Basel)2021https://conductscience.org/library/papers/34771591PubMed
1715050913Focus on hepatocellular carcinoma.Cancer Cell2004https://conductscience.org/library/papers/15050913PubMed
1829107679
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Lancet Oncol2017https://conductscience.org/library/papers/29107679PubMed
1928687477Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.J Hepatol2017https://conductscience.org/library/papers/28687477PubMed
2027579537Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.Oncotarget2016https://conductscience.org/library/papers/27579537PubMed

See all 33 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42305858
Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.
J Hepatocell Carcinoma2025https://conductscience.org/library/papers/42305858PubMed
40568833Sorafenib with or without co-interventions for hepatocellular carcinoma.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/40568833PubMed
36986832Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.Pharmaceutics2023https://conductscience.org/library/papers/36986832PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36737488

GET https://conductscience.org/api/papers/v1/36737488/references?page=2